Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Avalo Therapeutics' Shares Outstanding (Weighted Average) history spans 12 years, with the latest figure at $13.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 202.86% year-over-year to $13.4 million; the TTM value through Dec 2025 reached $13.4 million, up 202.86%, while the annual FY2025 figure was $13.4 million, 202.86% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $13.4 million in Q4 2025 per AVTX's latest filing, down from $14.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $88.6 million in Q1 2021 to a low of $39202.0 in Q4 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $10.0 million, with a median of $8.0 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 99.53% in 2022, then soared 1659.4% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $8.3 million in 2021, then crashed by 99.53% to $39202.0 in 2022, then surged by 608.45% to $277727.0 in 2023, then soared by 1493.7% to $4.4 million in 2024, then skyrocketed by 202.86% to $13.4 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Shares Outstanding (Weighted Average) are $13.4 million (Q4 2025), $14.0 million (Q3 2025), and $10.8 million (Q2 2025).